IL32 and primary cutaneous T-cell non-Hodgkin lymphoma: IL32 exerted both anti-tumor or pro-tumor effects in a cancer type dependent manner [40] and it has been reported to play a role in the formation and maintenance of lesions in cutaneous T-cell lymphoma (CTCL) [23].